The advantages of biologics over their small molecule predecessors are not without their costs. This e-book addresses the challenges in managing the biologic supply chain.
Emerging biopharmaceutical company teams up with clinical services company to stay on track with timelines and ensure funding milestones were met when faced with unexpected lack of bandwidth and limited global organizational experience.
World-class logistics facilities with state-of-the-art IT infrastructure implement new monitoring system allowing real-time monitoring and data recording, and meeting the requirements of FDA 21 CFR Part 11.
A small sized pharmaceutical company was approaching the final phases of a large phase III global multiple treatment arm oncology study that involved comparator drug. The study criteria required the client to provide study medication to patients active at the conclusion of the study until the drug would be commercially available, when it could then be prescribed to patients continuing treatment.
The global pharmaceutical sector is embarking on a transformational journey in which the supply chain will play an increasing strategic role. There will be a need for greater agility and speed to market.
To maintain the proper temperature of vaccines, West Pediatrics relies on Bluetooth low energy (BLE) data loggers for accurate and reliable temperature monitoring.
Europe and the United States are considered the world leaders in the safest pharmaceutical markets for patients. However, the US and Europe are also a lucrative target for drug crime.
Using workflow based software solutions to guide scientists through various processes in low to high throughput screening campaigns.
This webinar explores use cases showing how machine learning and analytics can help overcome the challenges facing the biopharma industry through more confident data-driven decisions.
Striving to bring the way we acquire, share and gain insights from scientific data, through a community and the framework for standardization and linked data.
Very few new molecular entities in active clinical development are readily bioavailable, and when dosed at escalated levels, even these may not be sufficiently absorbed.